August 28, 2020

To: Study leadership, HERO HCQ Trial

From: Clyde W. Yancy, MD, MSc
Chair, Data Safety and Monitoring Board, IIERO HCQ Trial

RE: Open meeting; August 27, 2020

The Data Safety and Monitoring Board for the HERO HCQ Trial met with the Executive Committee and Study Leadership for the HERO HCQ trial. Representation from the Data Coordinating Center was present as well.

Progress to date was reviewed; ongoing other clinical trial issues testing hydroxychloroquine were discussed; updates RE: study recruitment was reviewed; overall study status was evaluated; questions were fully addressed.

RE: Closed meeting; August 27, 2020

As per protocol, an interim analysis was completed of the first 1,000 patients. Outcomes and safety were assessed.

CONCLUSION & RECOMMENDATION

The DSMB commends the study team and study sites on execution of the HERO HCQ Trial and recommends continuation of the study as per protocol under the guidance of the Executive Committee.

Sincerely,

Clyde W. Yancy, MD, MSc

On behalf of DSMB members:

Adaora Adimora, MD
Scott Evans, PhD
Arthur Kim, MD
John Lantos, MD
Jennifer Silvey-Cason, GN, EMTP